Table 2 Baseline characteristics of non-valvular AF patients with DM after propensity score-based stabilized weights
|  | NOACs | NOACs (A + D+R + E) (n = 20,967) | Warfarin (n = 5812) | ASMD | |||
|---|---|---|---|---|---|---|---|
Apixaban n = 3249 | Dabigatran n = 6531 | Edoxaban n = 1389 | Rivaroxaban n = 9798 | NOACs vs. Warfarin | |||
Age | |||||||
 (Mean ± STD) | 75.6 ± 10 | 73.5 ± 10.1 | 74.9 ± 9.9 | 75 ± 10.1 | 74.6 ± 10.1 | 74.5 ± 10.3 | 0.0118 |
 < 65 | 499.76 (15.6%) | 1329.46 (20.3%) | 226.27 (16.8%) | 1619.19 (16.5%) | 3674.69 (17.6%) | 992.87 (17.8%) | 0.0129 |
 65–74 | 923.58 (28.8%) | 2109.08 (32.3%) | 396.11 (29.4%) | 2894.27 (29.5%) | 6323.04 (30.3%) | 1658.22 (29.8%) |  |
 75–84 | 1163.61 (36.3%) | 2278.34 (34.9%) | 506.75 (37.7%) | 3656.43 (37.3%) | 7605.13 (36.4%) | 2030.02 (36.4%) |  |
 > 85 | 620.66 (19.4%) | 818.07 (12.5%) | 216.63 (16.1%) | 1627.86 (16.6%) | 3283.22 (15.7%) | 891.61 (16%) |  |
Male | 1673.4 (52.2%) | 3788.91 (58%) | 730.05 (54.3%) | 5027.21 (51.3%) | 11,219.58 (53.7%) | 2981.44 (53.5%) | 0.0044 |
CHA2DS2-VASc (mean ± STD) | 4.6 ± 1.6 | 4.3 ± 1.6 | 4.4 ± 1.5 | 4.5 ± 1.7 | 4.5 ± 1.6 | 4.4 ± 1.6 | 0.0184 |
HAS-BLED (mean ± STD) | 3.2 ± 1.1 | 3 ± 1.1 | 3.1 ± 1.1 | 3.1 ± 1.1 | 3.1 ± 1.1 | 3 ± 1.1 | 0.0491 |
Hypertension | 2646.3 (82.5%) | 5147.03 (78.8%) | 1117.08 (83%) | 7823.89 (79.9%) | 16,734.29 (80.1%) | 4438.09 (79.6%) | 0.0122 |
Dyslipidemia | 2131.33 (66.5%) | 4013.75 (61.4%) | 964.54 (71.7%) | 6272.89 (64%) | 13,382.51 (64.1%) | 3545.77 (63.6%) | 0.0094 |
Chronic live disease | 448.27 (14%) | 836.45 (12.8%) | 211.38 (15.7%) | 1335.81 (13.6%) | 2831.92 (13.6%) | 745.06 (13.4%) | 0.0056 |
Chronic kidney disease | 884.71 (27.6%) | 1165.76 (17.8%) | 411.07 (30.6%) | 2318.11 (23.7%) | 4779.66 (22.9%) | 1290.66 (23.2%) | 0.0066 |
Chronic lung disease | 415.03 (12.9%) | 751.11 (11.5%) | 161.41 (12%) | 1403.16 (14.3%) | 2730.7 (13.1%) | 747.12 (13.4%) | 0.0099 |
Gout | 706.18 (22%) | 1152.6 (17.6%) | 317.42 (23.6%) | 1975.72 (20.2%) | 4151.94 (19.9%) | 1105.89 (19.8%) | 0.0009 |
Congestive heart failure | 461.45 (14.4%) | 721.17 (11%) | 174.76 (13%) | 1401.59 (14.3%) | 2758.96 (13.2%) | 770.92 (13.8%) | 0.0185 |
Chronic ischemic heart disease | 490.98 (15.3%) | 764.79 (11.7%) | 206.47 (15.3%) | 1457.45 (14.9%) | 2919.68 (14%) | 740.87 (13.3%) | 0.0202 |
Peripheral artery disease | 294.56 (9.2%) | 615.97 (9.4%) | 126.94 (9.4%) | 961.97 (9.8%) | 1999.44 (9.6%) | 531.89 (9.5%) | 0.0010 |
Stroke | 693.74 (21.6%) | 1497.7 (22.9%) | 189.25 (14.1%) | 2161.77 (22.1%) | 4542.45 (21.8%) | 1175.9 (21.1%) | 0.0160 |
Malignancy | 365.73 (11.4%) | 562.12 (8.6%) | 160.26 (11.9%) | 1055.43 (10.8%) | 2143.54 (10.3%) | 578.15 (10.4%) | 0.0037 |
PCI | 324.92 (10.1%) | 414.45 (6.3%) | 143.9 (10.7%) | 889.57 (9.1%) | 1772.84 (8.5%) | 459.64 (8.3%) | 0.0088 |
CABG | 35.34 (1.1%) | 30.41 (0.5%) | 10.85 (0.8%) | 90.42 (0.9%) | 167.02 (0.8%) | 44.51 (0.8%) | 0.0001 |
History of bleeding | 77.02 (2.4%) | 118.84 (1.8%) | 24.55 (1.8%) | 229.26 (2.3%) | 449.66 (2.2%) | 119.51 (2.1%) | 0.0006 |
Use of NSAIDs | 908.1 (28.3%) | 1567.68 (24%) | 380.44 (28.3%) | 2591.36 (26.5%) | 5447.58 (26.1%) | 1477.57 (26.5%) | 0.0099 |
Use of PPI | 470.21 (14.7%) | 662.62 (10.1%) | 177.39 (13.2%) | 1261.57 (12.9%) | 2571.79 (12.3%) | 690.04 (12.4%) | 0.0021 |
Use of H2 blocker | 1136.31 (35.4%) | 2108.48 (32.3%) | 452.75 (33.6%) | 3266.7 (33.3%) | 6964.24 (33.3%) | 1891.32 (33.9%) | 0.0127 |
Use of ACEI/ARB | 2179.74 (68%) | 4473.09 (68.5%) | 923.23 (68.6%) | 6739.93 (68.8%) | 14,315.99 (68.5%) | 3807.33 (68.3%) | 0.0048 |
Use of beta-blocker | 2033.15 (63.4%) | 3832.74 (58.7%) | 905.14 (67.3%) | 6041.78 (61.7%) | 12,812.82 (61.4%) | 3462.48 (62.1%) | 0.0164 |
Use of verapamil or diltiazem | 835.94 (26.1%) | 1555.98 (23.8%) | 260.29 (19.3%) | 2647.44 (27%) | 5299.65 (25.4%) | 1421.74 (25.5%) | 0.0032 |
Use of statin | 1524.64 (47.5%) | 2787.22 (42.7%) | 662.45 (49.2%) | 4428.17 (45.2%) | 9402.48 (45%) | 2467.58 (44.3%) | 0.0150 |
Use of APT | 557.85 (17.4%) | 1634.37 (25%) | 163.4 (12.1%) | 2288.62 (23.4%) | 4644.24 (22.2%) | 1275.11 (22.9%) | 0.0156 |
Use of metformin | 1464.25 (45.7%) | 3276.26 (50.1%) | 551.96 (41%) | 4424.87 (45.2%) | 9717.34 (46.5%) | 2605.79 (46.8%) | 0.0047 |
Use of SU | 1213.44 (37.8%) | 2703.68 (41.4%) | 443.81 (33%) | 3613.42 (36.9%) | 7974.35 (38.2%) | 2150.56 (38.6%) | 0.0085 |
Use of glinide | 316.99 (9.9%) | 545.52 (8.4%) | 104.16 (7.7%) | 941.11 (9.6%) | 1907.78 (9.1%) | 524.66 (9.4%) | 0.0098 |
Use of acarbose | 327.99 (10.2%) | 675.87 (10.3%) | 110.92 (8.2%) | 954.94 (9.8%) | 2069.72 (9.9%) | 564.11 (10.1%) | 0.0072 |
Use of glitazone | 187.7 (5.9%) | 380.2 (5.8%) | 64.64 (4.8%) | 470.95 (4.8%) | 1103.49 (5.3%) | 294.35 (5.3%) | 0.0001 |
Use of insulin | 981.92 (30.6%) | 1499.29 (22.9%) | 316.6 (23.5%) | 2823.21 (28.8%) | 5621.01 (26.9%) | 1541.1 (27.7%) | 0.0168 |
Use of SGLT2i | 62.44 (2%) | 52.38 (0.8%) | 48.25 (3.6%) | 109.87 (1.1%) | 272.94 (1.3%) | 19.75 (0.4%) | 0.1057 |